BamSEC and AlphaSense Join Forces
Learn More

Sigilon Therapeutics Inc – Material Contracts

Formerly NASDAQ: SGTX
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.4
from 10-Q 2 pages ​ Sigilon Therapeutics, Inc. Non-Employee Director Compensation Policy
12/34/56
EX-10.3
from 10-Q 12 pages Sigilon Therapeutics, Inc. 2020 Employee Stock Purchase Plan
12/34/56
EX-10.2
from 10-Q 17 pages ​ Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan
12/34/56
EX-10.1
from 10-Q 13 pages ​ Sigilon Therapeutics, Inc. 2016 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 22 pages Form of Contingent Value Rights Agreement
12/34/56
EX-10.36
from 10-K 4 pages Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan Restricted Stock Unit Agreement
12/34/56
EX-10.27
from 10-K 2 pages ​ ​ ​ ​ ​ ​ October 23, 2019 ​ Josias Fantato De Pontes ​ ​ Re: Employment by Sigilon, Inc. ​ ​ Dear Josias: ​
12/34/56
EX-10.26
from 10-K 6 pages ​ ​ ​ ​ ​ ​ January 12, 2022 via Electronic Mail ​ Qing Sarah Yuan, PH.D. ​ Dear Sarah, on Behalf of Sigilon Therapeutics, Inc. (The “Company”), I Am Delighted to Make This Conditional Offer of Employment With the Company. This Offer Letter (The “Offer Letter”) and the Accompanying Documents and Agreements Summarize and Set Forth Important Terms About Your Employment With the Company. 1. Starting Date, Position, and Duties. ​
12/34/56
EX-10.24
from 10-K 16 pages ​ ​ ​ ​ ​ ​ February 10, 2023 ​ by Hand & Electronic Delivery ​ May Orfali, M.D. ​ Dear May: ​
12/34/56
EX-10.23
from 10-K 9 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sigilon Therapeutics, Inc. if Publicly Disclosed. ​ Consulting Agreement [May Orfali, MD, Mba]
12/34/56
EX-10.1
from 10-Q 5 pages First Amendment to Research Collaboration and Exclusive License Agreement
12/34/56
EX-10.28
from 10-K 9 pages Consulting Agreement [May Orfali, MD, Mba]
12/34/56
EX-10.27
from 10-K 10 pages August 4, 2021 by Hand & Electronic Delivery Deya Corzo, M.D. the Purpose of This Letter Agreement (This “Agreement”) Is to Confirm the Terms of the Remainder of Your Employment With Sigilon Therapeutics, Inc. (The “Company”) and Your Resignation From Your Employment With the Company, as Follows: 1. Transition Period and Separation Date
12/34/56
EX-10.26
from 10-K 2 pages September 26, 2018 Deya Corzo, MD ​ Re: Employment by Sigilon, Inc. ​ Dear Deya
12/34/56
EX-10.25
from 10-K 5 pages ​ May 25, 2021 ​ via Electronic Mail ​ Philip Ashton-Rickardt, PH.D. ​ Dear Philip, ​ on Behalf of Sigilon Therapeutics, Inc. (The “Company”), I Am Delighted to Make This Conditional Offer of Employment With the Company. This Offer Letter (The “Offer Letter”) and the Accompanying Documents and Agreements Summarize and Set Forth Important Terms About Your Employment With the Company. ​ 1. Starting Date, Position, and Duties. ​
12/34/56
EX-10.24
from 10-K 5 pages ​ October 25, 2021 ​ via Electronic Mail ​ May Orfali, MD, Mba ​ Dear May, ​ on Behalf of Sigilon Therapeutics, Inc. (The “Company”), I Am Delighted to Make This Conditional Offer of Employment With the Company. This Offer Letter (The “Offer Letter”) and the Accompanying Documents and Agreements Summarize and Set Forth Important Terms About Your Employment With the Company. ​ 1. Starting Date, Position, and Duties. ​
12/34/56
EX-10.13
from 10-K 3 pages ​ Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sigilon Therapeutics, Inc. if Publicly Disclosed. ​ Massachusetts Institute of Technology and Sigilon Therapeutics, Inc. ​ Sixth Amendment
12/34/56
EX-10.1
from 10-Q 3 pages Massachusetts Institute of Technology ​ and ​ Sigilon Therapeutics, Inc. ​ Fifth Amendment
12/34/56
EX-10.1
from 10-Q 8 pages Consulting Agreement
12/34/56
EX-10.11
from 10-K 2 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Would Likely Cause Competitive Harm to Sigilon Therapeutics, Inc. if Publicly Disclosed. ​ Massachusetts Institute of Technology and Sigilon Therapeutics, Inc. ​ Fourth Amendment ​
12/34/56